IC14 Flashcards

1
Q

Role of Vit D

A

helps Calcium to be absorbed from GIT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What happens when there is low Ca

A

PTH secretion will incr, causing incr bone resorption and reabsorption of Ca in renal distal tubule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

At clinical doses, PTH analogues act more like a _____

A

anabolic agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Osteoclast stimulates bone____

A

resorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Osteoblast stimulates bone___

A

growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

RANKL and sclerostin are produced by ____

A

osteocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Role of sclerostin

A

Sclerostin binds to osteoblast -> inhibit WNT signalling -> repress dy/dx of osteoblast & ability to grow new bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Role of RANKL

A

Stimulates osteoclast to break down bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Example of RANKL inhibitor

A

Denosumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Role of anti-resorptive agents

A

Blocks bone breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Examples of anti-resorptive agents

A
  • Bisphosphonates
  • denosumab
  • oestrogen
  • calcitonin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA of bisphosphonates

A

Slow bone loss by incr osteoclast cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

In what situation is bisphosphonate use > 5 years appropriate?

A

10yr total fracture risk > 20% OR prior vertebrae fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOA of denosumab

A

Human mAb Inhibits RANKL -> prevents osteoclast development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Administration of denosumab (route & frequency)

A

SC injection every 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What to co-administer with denosumab

A

1000mg Ca +/- (min) 400 IU vit D daily

17
Q

Discontinuation of denosumab may cause ___

A

Risk of spinal column fractures

18
Q

Oestrogens MOA

A

Helps maintain bone density

19
Q

What is raloxifene

A

Selective oestrogen receptor modulator

20
Q

MOA of raloxifene

A

Mixed oestrogen receptor agonism and antagonism
-> Mimics effects of oestrogen on bone density in postmenopausal women.

21
Q

Risk of using oestrogen therapy

A
  1. Incr risk of breast cancer
  2. Incr risk of blood clots
22
Q

What is calcitonin and how is it secreted

A

Peptide hormone secreted by parafollicular cells of thyroid gland

23
Q

Dosage forms for calcitonin

A

IV/ IM/ SC/ nasal spray route

24
Q

Examples of anabolic agents

A
  • romosozumab
  • parathyroid hormone therapy
25
Q

MOA of romosozumab

A

Humainised mouse mAb -> inhibits sclerostin activity -> incr bone formation & decr bone resorption

26
Q

Administration of romosozumab

A

SC injection once a month

27
Q

When is romosozumab used

A

For women at high fracture risk / those who failed or intolerant to other therapies

28
Q

Example of Parathyroid hormone similars

A

teriparatide

29
Q

Administration of Parathyroid hormone similars

A

Once daily SC injection

30
Q

Max tx duration for parathyroid hormone similars

A

24 months

31
Q

IV zoledronate administration

A

Once a year

32
Q

Oral alendronate administration

A

Once a week

33
Q

Oral risedronate administration

A

Once a week or month